Literature DB >> 20677402

Current status of human papillomavirus vaccines.

Barbara Ma, Richard Roden, T-C Wu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20677402      PMCID： PMC2917202          DOI： 10.1016/s0929-6646(10)60081-2

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN： 0929-6646            Impact factor:   3.282


× No keyword cloud information.
  8 in total

Review 1.  Currently approved prophylactic HPV vaccines.

Authors:  Diane M Harper
Journal:  Expert Rev Vaccines       Date:  2009-12       Impact factor: 5.217

2.  Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly.

Authors:  M Li; T P Cripe; P A Estes; M K Lyon; R C Rose; R L Garcea
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 3.  Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes.

Authors:  Geoffrey P Garnett; Jane J Kim; Katherine French; Sue J Goldie
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

Review 4.  Perspectives for preventive and therapeutic HPV vaccines.

Authors:  Ken Lin; Kimberley Doolan; Chien-Fu Hung; T C Wu
Journal:  J Formos Med Assoc       Date:  2010-01       Impact factor: 3.282

5.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

Authors:  Gemma G Kenter; Marij J P Welters; A Rob P M Valentijn; Margriet J G Lowik; Dorien M A Berends-van der Meer; Annelies P G Vloon; Farah Essahsah; Lorraine M Fathers; Rienk Offringa; Jan Wouter Drijfhout; Amon R Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Sjoerd H van der Burg; Cornelis J M Melief
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

6.  Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.

Authors:  Mark H Einstein; Mira Baron; Myron J Levin; Archana Chatterjee; Robert P Edwards; Fred Zepp; Isabelle Carletti; Francis J Dessy; Andrew F Trofa; Anne Schuind; Gary Dubin
Journal:  Hum Vaccin       Date:  2009-10-14

7.  Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.

Authors:  Dominique Fraillery; David Baud; Susana Yuk-Ying Pang; John Schiller; Martine Bobst; Nathalie Zosso; Françoise Ponci; Denise Nardelli-Haefliger
Journal:  Clin Vaccine Immunol       Date:  2007-08-08

8.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506
  8 in total
  4 in total

Review 1.  Emerging human papillomavirus vaccines.

Authors:  Barbara Ma; Bharat Maraj; Nam Phuong Tran; Jayne Knoff; Alexander Chen; Ronald D Alvarez; Chien-Fu Hung; T-C Wu
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-19       Impact factor: 4.191

2.  The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value.

Authors:  Mario Songane; Volker Grossmann
Journal:  PLoS One       Date:  2021-01-11       Impact factor: 3.240

Review 3.  Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs.

Authors:  Rahul Bhattacharjee; Lamha Kumar; Archna Dhasmana; Tamoghni Mitra; Abhijit Dey; Sumira Malik; Bonglee Kim; Rohit Gundamaraju
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

4.  Virus like particles as a platform for cancer vaccine development.

Authors:  Hui Kian Ong; Wen Siang Tan; Kok Lian Ho
Journal:  PeerJ       Date:  2017-11-15       Impact factor: 2.984
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.